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Abstract: The cyclin-dependent kinase (CDK) inhibitors purvalanol and roscovitine are therapeutic agents that control cell proliferation
through regulating cell-cycle machinery. They also affect polyamine (PA) metabolism, which is activated in malignant tissues. Therefore,
PA catabolism became a remarkable target in cancer therapies. Induction of the PA catabolic enzyme spermidine/spermine N1acetyltransferase (SSAT) is under the control of transcription factors such as NFκB and PPARγ. The purpose of this study was to
investigate the therapeutic potential of CDK inhibitors in combination with PAs in MCF-7 breast cancer cells. In order to understand
the involvement of PA catabolic enzyme SSAT in this process we also checked its transcriptional regulation in the presence of CDK
inhibitors. MCF-7 cells were exposed to CDK inhibitors in the absence or presence of Spd and Spm. Cell viability loss was evaluated
by MTT assay. Apoptosis was determined by annexin-V/PI staining using FACS flow. The SSAT transcription level was measured by
qRT-PCR. Intracellular PA pool was determined by HPLC. Protein expressions were assessed by western blotting. We found that CDK
inhibitors decreased cell viability in a time-dependent manner and induced apoptosis. Co-treatment of Spd or Spm with CDK inhibitors
prevented the apoptotic potential of both drugs. Purvalanol increased SSAT expression levels in a time-dependent manner. Although
the induction of SSAT by purvalanol resulted in the activation of NFκB at early time points, induction was accomplished by PPARγ as
a late response after purvalanol treatment. We concluded that both transcriptional control mechanisms could be responsible for SSAT
regulation in a time-dependent manner.
Key words: Polyamines, SSAT, purvalanol, PPARγ, NFκB

1. Introduction
The interaction of cyclin-dependent kinases (CDK) and
their specific cyclin counterparts regulates cell-cycle
progression. Deregulation of the cell cycle induces the
transformation of normal cells into malignant cells. The
CDK inhibitors purine-derived purvalanol or roscovitine
(ROSC, CYC202) block the ATP binding sites of CDK1,
CDK2, CDK5, and CDK7 and cause cell-cycle arrest at
G1/S or G2/M, which leads to apoptosis in various cancer
cell lines.
The polyamines (PAs) putrescine (Put), spermidine
(Spd), and spermine (Spm) are essential amine derivatives
with cationic properties and have important roles in cell
growth and differentiation. PA levels are found at higher
concentrations in malignant tissues than in normal tissues
(Simoneau et al., 2001), which indicates the potential of
these molecules as targets for antineoplastic therapy. PA
catabolism is under the control of spermidine/spermine
* Correspondence: p.obakan@iku.edu.tr
** Authors with equal contribution.

712

N1-acetyltransferase (SSAT) and polyamine oxidase (PAO).
While SSAT establishes the first step of catabolic activity
by acetylating Spd or Spm, it also prepares these molecules
to be excreted from the cell. SSAT activity is also required
to present substrates for PAO, which oxidizes acetylated
forms as the second step of PA catabolism. The byproducts
of these reactions are H2O2 and 3-acetoaminopropanol.
SSAT is upregulated by various chemotherapeutic agents
in several tumor types (Casero et al., 2003; MurrayStewart et al., 2003; Zahedi et al., 2003). CDK inhibitors
could trigger apoptotic machinery by activating SSAT and
related reactive oxygen species in different cancer cell lines
such as colon and prostate (Arisan et al., 2012; Coker et
al., 2013; Obakan et al., 2013; Obakan et al., 2014). Recent
studies suggest that Spd and Spm exert multiple effects
including antioxidant and antiinflammatory responses.
While Spd treatment prolonged the life span of several
model organisms by preventing the protein damage that
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caused oxidative aggregation (Eisenberg et al., 2009), Spm
might promote drug-induced apoptosis or sensitivity to
therapy models in cancer cells (Agostinelli et al., 2007).
In primary human cells, Spm treatment resulted in an
intracellular increase of reactive oxygen species (ROS) and
apoptosis triggered via mitochondria membrane potential
loss (Schiller et al., 2005). However, Spm-mediated cell
survival was detected in neuron cells in a concentrationdependent manner (Chu et al., 1994).
The transcriptional regulation of SSAT is under the
control of PAs, which might also affect other important
transcription factors: the nuclear factor kappa-light-chain
enhancer of activated B-cells (NFκB) and peroxisomeproliferator–activated receptor gamma (PPARγ). NFκB
plays crucial roles in the development and progression
of cancer. It regulates more than 400 genes involved in
cell survival, cell proliferation, invasion, angiogenesis,
and metastasis (Sethi et al., 2008; Yadav et al., 2010).
Homo- or heterodimers of the Rel family proteins, p50/
NF-κB1, p52/NF-κB2, p65/RelA, and c-Rel are the main
molecules to form NFκB dimers (Karakas and Gozuacik,
2014). Under normal conditions, NFκB dimers are
located in the cytoplasm through a physical association
with IκBα in most cell types (Baeuerle et al., 1988).
When the cells are stimulated by tumor necrosis factor
(TNF), lipopolysaccharide (LPS), interleukin-1 (IL-1), or
chemokine (CD40) signals under stress conditions, IκBα
becomes hyperphosphorylated by IκBα kinase (IKK) on
distinct serine residues; this hyperphosphorylation induces
the proteolytic degradation of IκBα. The degradation of
IκBα eventually leads to the dissociation of NFκB dimers,
allowing its translocation to the nucleus, where it binds
with high specificity to the enhancer sequences in the
promotors of target genes. PPARγ belongs to the nuclear
hormone receptor superfamily and plays an essential role
in the regulation of cellular differentiation, development,
metabolism, and tumorigenesis. Two PPARγ response
elements in the promoter of the SSAT gene were identified
(Babbar et al., 2003).
Our aim was to investigate the possible role of CDK
inhibitors on the SSAT expression profile by examining
the modulation of NFkB or PPARγ in estrogen-positive
MCF-7 breast cancer cells. We found that purvalanol
could activate SSAT expression which led to a decrease
in total intracellular PA content. The induction of SSAT
by purvalanol could be accomplished by PPARγ as a
late response, whereas p65 was responsible for SSAT
upregulation as an early response (within 4 h). The
upstream regulatory elements of NFκB, IκKα, and IκBα
were activated by purvalanol treatment in MCF-7 cells. As
a result of a similar modulation of PPARγ in the presence of
purvalanol we concluded that both transcriptional control
mechanisms could be responsible for SSAT regulation in a
time-dependent manner.

2. Materials and methods
2.1. Cell lines
MCF-7 breast cancer cells (ATCC) were grown in DMEM
medium (PAN Biotech) supplemented with 10% fetal
bovine serum (PAN Biotech) and penicillin-streptomycin
(10,000 U penicillin/mL; 10 mg streptomycin/mL) at 37°
C in a humidified 5% CO2 incubator. Cells were seeded
overnight and then treated with purvalanol (Tocris
Bioscience, Bristol, UK), 10 mM stock concentration in
DMSO and stored at –20 °C, or roscovitine (Calbiochem,
La Jolla, CA, USA), 10 mM stock concentration in
DMSO, and N-acetylcysteine (NAC) (Sigma Aldrich, St
Louis, MO, USA). The effect of serum amine oxidases as
a possible source of ROS was excluded by their inhibitor,
aminoguanidine (Sigma Aldrich, St Louis, MO, USA).
2.2. Cell viability assay
The effect of CDK inhibitors on cell viability was determined
by a colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide) assay (Roche, Indianapolis,
IN, USA). MCF-7 cells were plated at 1 × 105 cells/well in 96well plates, allowed to attach overnight, and treated for 24
h with various concentrations of purvalanol or roscovitine
(20 and 25 µM, respectively). After a 24 h treatment, 10 µL
of MTT (5 mg/mL) was added to the culture medium and
incubated for 4 h. Following aspiration of the medium, 200
µL of DMSO was added to dissolve the formazan crystals.
The absorbance of the suspension at 570 nm was measured
with a microplate reader (Bio-Rad, Hercules, CA, USA).
2.3. Flow cytometric analysis of apoptosis
Cells (2 × 105 cells/well) were seeded in 6-well plates and
then treated with purvalanol and roscovitine for 24 h (20
and 25 µM, respectively). Cells were collected and washed
twice with cold 1X PBS. The cell pellet was resuspended in
300 µL of binding buffer and incubated with 3 µL of FITCconjugated annexin-V and 3 µL of PI (BD Biosciences, San
Jose, CA, USA) for 15 min at room temperature in the dark
at 37 °C in a humidified 5% CO2 incubator. The samples
were analyzed by flow cytometry (Accuri Cytometers, Inc.,
Ann Arbor, MI, USA)
2.4. Determination of reactive oxygen species (ROS) by
DCFH-DA staining
MCF-7 cells were seeded in 6-well plates (1 × 105 cells/
well). Following exposure of cells to purvalanol or
roscovitine for 24 h, media was carefully discarded. Cells
were trypsinized, resuspended in 1X PBS, and stained with
DCFH-DA (0.5 µM) (Molecular Probes, Inc., Eugene,
OR, USA) for 45 min in a 5% CO2 incubator. After the
incubation period we added propidium iodide 0.5 µL/0.5
mL/tube (final concentration = 1 µg/mL) and proceeded
to flow cytometry analysis (Attune, Applied Biosystems).
Living cells, which are PI negative, were selected by FACS
gating. In these living cells we recorded the fluorescence of
DCF on the FL-1 channel (525 nm).
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2.5. RNA extraction and qRT-PCR
Total RNA was isolated by TRIzol (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions.
cDNAs from each samples were obtained by using iScript
cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The
cDNAs were subjected to quantitative real-time PCR.
Forty cycles of reactions were performed under the
conditions of denaturation for 30 s at 95 °C; annealing was
performed for 30 s at 55 °C and extension for 30 s at 72 °C.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal standard. PCRs were performed
in separate tubes in duplicate in a MiniOpticon (Bio-Rad,
Hercules, CA, USA). SSAT cDNAs were amplified using
SSAT primers purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). GAPDH internal standard cDNA
was also amplified using the following primers:
forward, 5’-CGGAGTCAACGGATTTGGTCGTAT-3’;
reverse, 5’-AGCCTTCTCCATGGTGGTGAAGAC -3’.
2.6. Western blot analysis
For total protein extraction from the MCF-7 cell line, cells
were lysed in ProteoJET mammalian cell lysis reagent
(Fermentas, Hanover, MD, USA) containing total protease
inhibitor cocktail (Fermentas, Hanover, MD, USA). Total
cellular protein level was determined by the Bradford
method (Bio-Rad). For cytoplasmic and nuclear protein
extraction a NE-PER nuclear and cytoplasmic extraction
reagent kit (Thermo Scientific, Rockford, IL, USA) was
used, according to manufacturer’s instructions.
To proceed to immunoblotting, 20 µg of total protein
was loaded onto 12% SDS-polyacrylamide gels and
subjected to electrophoresis. Gels were electrophoretically
transferred to polyvinylidene difluoride (PVDF)
membranes (Roche, Mannheim, Germany). PVDF
membranes were rinsed in tris buffer saline with Tween
20 (TBS-T) (10 mM Tris-HCl, pH 8; 0.05% Tween 20) and
blocked in a buffer of TBS-T containing 5% skim milk
overnight at 4 °C. PVDF membranes were then incubated
with primary antibodies (SSAT, p65, IκBα, P-IκBα,
P-IKKα, P-p65, and PPARγ; β-tubulin used as loading
control) (Cell Signaling Technology, Danvers, MA, USA)
overnight at 4 °C. Membranes were then incubated with
appropriate secondary antibodies (anti-rabbit or antimouse IgG) conjugated to horseradish peroxidase for 2 h at
room temperature. Membranes were developed using ECL
chemiluminescence reagents (Amersham Biosciences,
Princeton, NJ, USA) and exposed to X-ray films (Kodak).
2.7. Measurement of polyamine levels
Cells (3 × 105) were harvested from 6-well culture petri
dishes, washed twice with PBS, and pelletized. The cell
pellet was treated with 50% tricholoroacetic acid and
centrifuged at 13,200 rpm for 20 min. Supernatant was
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retained, and benzoylation was performed. PA levels were
determined by HPLC (Agilent Technologies, Santa Clara,
CA, USA), as described by Singh et al. (1989).
2.8. Statistics
Numerical data were obtained from the averages of at least
two experiments and analyzed with Graph Pad version
4.04 software. To determine significant alterations, a twotailed unpaired t-test was performed. Immunoblotting
results were repeated at least twice, and ImageJ software
was used to measure the band intensities.
3. Results
3.1. Co-treatment of Spd and Spm with each CDK
inhibitor altered the cytotoxic effect
To understand the effect of the potential role of PAs on the
cytotoxic effect of purvalanol and roscovitine, a MTT cell
viability assay was performed in MCF-7 cells. As shown
in Figure 1a, purvalanol (20 µM) and roscovitine (25 µM)
decreased cell viability by 40% and 50%, respectively.
Spd and Spm co-treatment at a 10 µM concentration for
24 h prevented CDK inhibitor-induced cell viability loss
(Figure 1a).
In order to understand the effects of Spd or Spm
co-treatments on CDK inhibitor-induced apoptosis,
we performed the annexin-V/PI staining and analyzed
apoptotic populations with a flow cytometer. As shown in
Figure 1b, early and late apoptotic population percentages
increased following purvalanol and roscovitine treatments
by 16% and 12%, respectively, compared to untreated
control samples. However, while Spd and Spm did not
cause apoptotic cell death, as compared to control samples,
combined treatments with either Spd or Spm significantly
decreased drug-induced apoptosis (Figure 1b). Spd cotreatment prevented apoptotic effects of purvalanol and
roscovitine by 13% and 12%, respectively. These rates were
17% and 10% when MCF-7 cells were treated with each
CDK inhibitor in the presence of Spm.
3.2. Co-treatment of polyamines prevented ROS
generation
Generation of ROS, an apoptosis-inducing factor in cancer
cells, is generally correlated with the active PA catabolic
machinery. We found that ROS generation was triggered
after CDK inhibitor treatment, and additional polyamine
treatment prevented drug-induced accumulation of
ROS in MCF-7 cells (Figure 2a). Intracellular ROS
accumulation was detected with DCFH-DA staining
following drug treatment for 24 h. Co-treatment of cells
with either Spd or Spm prevented ROS accumulation
induced by purvalanol and roscovitine, which supports
the suggestion that exogenous PAs might withdraw the
apoptotic effect of CDK inhibitors via ROS accumulation
in MCF-7 cells. As shown in Figure 2b, the antioxidant
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Figure 1. Purvalanol and roscovitine induce cell death in MCF-7 breast cancer cells. a. Cells (1 × 104) were seeded into 96-well plate
and treated with purvalanol and roscovitine, either in the presence of Spm or Spd, for 24 h. MTT cell viability assay was performed.
The result shown is the average from three independent trials with at least four replicates. Statistical differences were analyzed using an
unpaired t-test; *P < 0.05. b. Apoptosis was evaluated with Annexin-V and PI staining following purvalanol and roscovitine treatment
by flow cytometry. Annexin-V FITC staining in x-axis and PI in y-axis. The number represents the percentage of healthy (lower-left),
early apoptotic (lower-right), late apoptotic (upper-right), and necrotic (upper-left) populations.
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Figure 2. Co-treatment of CDK inhibitors with PAs prevented reactive oxygen species (ROS) generation. a. MCF-7 cells were seeded in a
96-well plate (1 × 104 cell/well) and treated with purvalanol and roscovitine, with or without Spd and Spm, for 24 h. Following DCFDHDA (1 µg/mL) staining for 30 min, ROS generation was determined by flow cytometry. b. MCF-7 cells co-treated with CDK inhibitors
and 5 µM NAC. The MTT assay was performed to determine cell viability. The result shown is the average from three independent trials
with at least four replicates.
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SSAT gene expression (fold vs GAPDH)

N-acetylcysteine (NAC) protected MCF-7 cells against
purvalanol- and roscovitine-induced cell death by 30%
and 10%, respectively.
3.3. Depletion of intracellular polyamine pool was
correlated with SSAT induction
Since clarification of activated PA catabolic machinery
might induce apoptosis due to the generation of hydrogen
peroxide and aldehydes in response to chemotherapeutic
agents, we checked the time-dependent effect of purvalanol
on the expression status of SSAT, the first-step enzyme of
PA catabolism by qRT-PCR method. As shown in Figure
3a, purvalanol treatment increased SSAT expression levels
within 8 h. Prolonged exposure to purvalanol caused a
fluctuation in gene expression within 24 h. According to
(a)
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Figure 3. Purvalanol induced SSAT gene expression in MCF7 cells. a. MCF-7 cells were treated with purvalanol in a timedependent manner and harvested, and total RNA was extracted
and used for qRT-PCR. SSAT expression was normalized to
GAPDH expression. Fold induction was calculated by dividing
normalized values of the sample by the control value. The result
was shown as the mean ± SD from three different experiments. b.
The effect of roscovitine or purvalanol on intracellular polyamine
levels was analyzed by HPLC.

qRT-PCR results, SSAT expression is mostly upregulated
within 12 h. Finally, as shown in Figure 3b, we also
determined the intracellular PA pool by HPLC. Both CDK
inhibitors depleted PA pool in MCF-7 cells.
3.4. NFκB and its upstream enzymes were downregulated
in response to purvalanol
The phosphorylation of IKKα, the upstream kinase of IκBα,
was also investigated to evaluate the potential role of NFκB
signaling in purvalanol-modulated polyamine metabolism
after CDK inhibitor treatment. Purvalanol treatment
caused dephosphorylation of p-IKKα, as well as p-IκBα,
within 24 h. Purvalanol was effective at dephosphorylating
p65 at Ser536 residue. However, roscovitine exerted a
lesser effect on the NFκB-signaling pathway (Figure 4a).
Therefore, we concluded that purvalanol modulated NFκB
signaling more effectively than roscovitine treatment in
MCF-7 breast cancer cells. These results were confirmed
by presentation of total protein expression levels of NFκB
p65 subunit and its regulatory upstream element IκBα,
which was altered in a time-dependent manner following
purvalanol treatment (Figure 4b). Exposing cells to
purvalanol decreased p65 expression within 2 h, but it
was restored following 4- and 12-h treatments. We also
checked the total expression level of PPARg, which is one
of the responsible transcription factors for SSAT, following
purvalanol treatment (Figure 4b). Purvalanol treatment
starting from 15 min upregulated the PPARg expression
level within 24 h. The nuclear translocation of p65 following
purvalanol treatment was shown by isolating nuclear/
cytoplasmic protein lysates in MCF-7 cells. As shown in
Figure 4c, translocation of p65 to the nucleus was prevented
after a 24-h purvalanol treatment. As p65 translocation
was prevented and polyamine levels decreased with 24
h purvalanol treatment through induction of SSAT, we
investigated the other SSAT-inducing transcription factor,
PPARγ. As shown in Figure 4c, translocation of PPARγ to
the nucleus was more effectively induced by purvalanol
than roscovitine in MCF-7 cells.
4. Discussion
The correct functional status of CDKs is required for the
achievement of the cell cycle. Therefore researchers are
focused on CDK-targeted therapies to block cell-cycle
progress to induce apoptosis in cancer cells. Purvalanol
and roscovitine are synthetic CDK inhibitors used in
the treatment of breast, prostate, and colon carcinomas
(Wesierska-Gadek et al., 2004; Arisan et al., 2011).
Roscovitine is the most studied CDK inhibitor and was
a strong apoptotic inducer in various cell lines. It exerts
its therapeutic effect by targeting cell cycle arrest at the
G1/S or G2/M phase transition points due to inhibition of
CDK1, CDK2, and CDK5 in lung and cervical cancer cells.
Although similar mechanisms are activated by purvalanol,
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Figure 4. Purvalanol and roscovitine suppress the NFκB signaling pathway and induce PPARγ. a. Expression profiles of pIKKα, IkBα,
and pNFκB were determined by immunoblotting after purvalanol treatment. b. Expression profiles of NFκB, IκBα, and PPARγ were
determined by immunoblotting following time-dependent purvalanol treatment in MCF-7 cells. β-Tubulin was used as a loading
control. c. Nuclear translocation of NFκB and PPARγ were determined by immunoblotting. β-Actin and histone H3 were used as
loading controls for cytoplasmic and nuclear fractions, respectively.
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less information is available to evaluate its potential
therapeutic effect in cancer cells. Previous studies showed
that purvalanol caused downregulation of Rb, cyclin E,
and cyclin A to block the cell cycle in mouse fibroblast
BP-A31 cells (Villerbu et al., 2002). In addition, nuclear
fragmentation due to purvalanol treatment was shown in
HT-29 cells (Villerbu et al., 2002). Similar to these results,
we found that both CDK inhibitors significantly decreased
cell viability compared to untreated cells within 24 h in
MCF-7 breast cancer cells (Figure 1a). Additional Spd or
Spm treatment prevented drug-induced cytotoxicity and
apoptosis (Figure 1b).
PAs are essential polycationic compounds that have
critical roles to regulate transcription, translation, and
proliferation in cellular homeostasis. The increase in total
PA levels was detected in malignant cells, and this promotes
cell proliferation. Therefore, PAs are suggested as attractive
targets for chemotherapeutic interventions. Intracellular
PA levels are involved in the regulation of cell proliferation
in different ways depending on their concentration and
metabolism. Spd and Spm are polycationic molecules,
and they stabilize the DNA/RNA (Obakan et al., 2014).
High intracellular levels of Spm induce production of
oxidative molecules that increase DNA damage and cell
death; either apoptosis or necrosis. In the present study,
exposure of cells to Spd and Spm protected cells from CDK
inhibitor-induced cell viability loss and apoptosis (Figures
1a and 1b). Our results were correlated with the finding
that co-treatment with Spd protected Ehrlich ascites
tumor cells from apoptosis induced by 1’-acetoxychavicol
acetate (Moffatt et al., 2000). In addition, similar to our
data, Spd treatment has been shown to suppress ageing on
yeast, flies, and worms (Eisenberg et al., 2009). Conversely,
Spm treatment triggered apoptosis via induction of
oxidative stress in a variety of cell types, including cardiac
myoblasts (Maccarrone et al., 2001; Hirano et al., 2006).
PA catabolic enzyme overexpression is known with
apoptosis-promoting roles due to generation of the toxic
byproducts hydrogen peroxide and aldehydes in response
to chemotherapeutic agents. In our previous studies, we
showed that CDK inhibitors are responsible for inducing
PA catabolic enzymes, PAO, and SSAT. As a response to
CDK inhibitor-induced PA catabolic enzyme levels, ROS
generation could be related to induction of SSAT. Previous
studies reported ROS generation is linked with DNA
damage and results in apoptosis (Casero et al., 2003; Arisan
et al., 2012). Our previous studies showed that purvalanol
and roscovitine induce ROS generation in LNCaP, DU145,
PC3 prostate cancer cells, and HCT116 colon cancer cells
(Arisan et al., 2012; Coker et al., 2013; Obakan et al.,
2014). Spm co-treated cells showed a greater increase in
DCFDH-DA staining than Spd co-treatment with CDK
inhibitor. In contrast to our results in MCF-7, when TNFα

combined with Spm, apoptosis was blocked due to the free
radical scavenger role of Spm (Naredi et al., 1994). Our
observation that N-acetylcysteine (NAC) protected MCF-7
breast cancer cells from CDK inhibitor-induced apoptosis
by inhibiting ROS accumulation also confirmed that both
CDK inhibitors could act by inducing ROS generation.
Similar to our results, in chemotherapeutic agents such
as docosahexaenoic acid apoptosis was triggered via ROS
generation, which could be inhibited with the NAC in
MCF-7 cells
In our previous work, we showed that purvalanol
and roscovitine induced SSAT expression and decreased
the intracellular polyamine levels in HCT116 colon
adenocarcinoma cells (Arisan et al., 2011). Because
polyamines are essential for malignant cell growth, in our
present paper we evaluated the effects of purvalanol on
PA catabolism and determined the mechanism by which
purvalanol was able to induce SSAT expression in a timedependent manner in MCF-7 cells. The induction of SSAT
is usually accompanied by a decrease in intracellular levels
of PA, in particular Spd and Spm. Our results indicated that
purvalanol at 20 µM led to a decrease in total PA levels after
24 h. Recent reports suggest that many chemotherapeutic
drugs such as polyamine analogues, BENSpm (Huang et
al., 2005), roscovitine (Coker et al., 2012), and sulindac
(Babbar et al., 2003) lead to the induction of SSAT and
a lower intracellular PA pool in MCF-7 and other cancer
cells.
The induction of SSAT due to purvalanol treatment led
us to investigate the involvement of SSAT transcription
factors, NKκB and PPARγ. The SSAT promoter sequence
has several potential responsive binding sites, -286, -594,
and -1735; three NKκB sites (Babbar et al., 2006). Aspirin
activates SSAT transcription via two NFκB response
elements (NRE) in the SSAT 5’ promoter flanking sequence
(Babbar et al., 2006). NKκB is formed by homo- and
hetero-dimers of p50 and p65 proteins in the cytoplasm.
They have been shown to play a role in tumor development
and control the expression of genes involved in cell-cycle
regulation and apoptosis (Basseres et al., 2006). For this
reason, we first investigated the NFκB regulatory proteins,
phosphorylated IKKβ, and the downstream target IκBα
phosphorylation. Phosphorylation of IκB is required
for its ubiquitination and proteasomal degradation by
allowing the release and activation of NFκB. In our
experimental system, purvalanol treatment decreased
IKKβ phosphorylation, and it could not phosphorylate
IκBα more significantly than roscovitine treatment.
This result suggested that the classical NKκB pathway
for translocation is blocked by CDK inhibitors. In
addition, both drugs dephosphorylated NKκB complex
member p65, which indicated that CDK inhibitors
prevented the translocation of NKκB to the nucleus
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after 24 h. It is well established that Spm treatment could
activate estrogen receptor (ER)-α and NFκB-mediated
transcription. Electromobility shift assay (EMSA) and
immunoprecipitation studies demonstrated that Spm
enhanced ERα-estrogen response element (ERE) and NRE
binding, which cause increased nuclear levels of NFκB
and provided stronger binding efficiency to DNA and
protein components for transcriptional initiation (Shah et
al., 2001). Similar to our results, epidermal growth factor
inhibitor celecoxib inhibited the translocation of NFκB
in A459, GLC82, and SW 1573 lung cancer cells (Chen
et al., 2008). BMS-345541 also blocks NFκB activation by
inhibition of IKKα in HTLV-1 (Agbottah et al., 2008). The
time-dependent expression profile of NKκB and IκBα also
showed that these proteins were downregulated following
purvalanol treatment in a time-dependent manner.
However, our results from qRT-PCR for SSAT showed
transcriptional induction reached the highest level in 24
h; we therefore investigated potential SSAT transcription
activators other than NKκB. We first determined the total
PPARγ expression level following purvalanol treatment
in a time-dependent manner. We found that total PPARγ
expression levels increased compared to untreated MCF7 cells in a fluctuating manner; however, 12 and 24 h
seemed critical because at these same time periods NKκB
expression downregulated, although SSAT expression
continued to increase. Therefore, we determined the
translocation profile of each transcription factor to the
nucleus. Either 24 h purvalanol or roscovitine treatment

totally inhibited the translocation of NKκB to the nucleus.
In addition, the cytoplasmic levels of NFκB decreased after
purvalanol treatment for 24 h. Furthermore, purvalanol
and roscovitine induced the translocation of PPARγ, as well
the cytoplasmic PPARγ, to the nucleus. PPARγ induction
is targeted to counteract hyperglycemia (Atanasov et al.,
2013). Interestingly, purvalanol has been shown to inhibit
NKκB and trigger apoptosis in human T-cell leukemia
virus type-1 (HTVL-1) (Agbottah et al., 2008). Therefore,
we conclude that although purvalanol could induce the
transcription of SSAT under control of NFκB as an early
response, NFκB expression begins to downregulate after
prolonged treatment with purvalanol in order to switch
off the NFκB-dependent survival signal. However, cells
could continue to express SSAT, and generate ROS and
apoptosis, after long-term purvalanol treatment under
control of PPARγ.
5. Conclusion
Our data demonstrated that there is a close relationship
between PPARγ and NFκB in SSAT transcription following
purvalanol treatment in MCF-7 cells. The purvalanol
exposure time is the critical factor for the induction of
SSAT expression in MCF-7 breast cancer cells.
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